Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.71 |
| ▸ | HTR1D | P28221 | 10/20 | 0.67 |
| ▸ | HTR1B | P28222 | 10/20 | 0.67 |
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26508337 | 0.97 | MPO (0.67) | MPOHTR1DHTR1BHTR2AHPGD | |
| SCHEMBL26508329 | 0.86 | HTR2A (0.65) | MPOHTR1DHTR1BHTR2AHTR1A | |
| SCHEMBL2933511 | 0.83 | HTR1A (0.75) | MPOHTR1DHTR1BHTR2AHTR1A | |
| SCHEMBL8506914 | 0.83 | HTR1D (0.71) | MPOHTR1DHTR1BHTR2ABRD4 | |
| SCHEMBL27095364 | 0.83 | HTR7 (0.71) | MPOHTR1DHTR1BHTR2AHTR1A | |
| SCHEMBL733997 | 0.83 | MPO (1.00) | MPOHTR1DHTR1BHTR2AHTR1A | |
| SCHEMBL26989598 | 0.82 | HTR7 (0.70) | MPOHTR1DHTR1BHTR2AHTR1A | |
| SCHEMBL733711 | 0.82 | MPO (0.97) | MPOHTR1DHTR1BHTR2AHTR1A | |
| SCHEMBL6969548 | 0.81 | HTR1D (0.73) | MPOHTR1DHTR1BHTR2ABRD4 | |
| SCHEMBL8506288 | 0.81 | HTR1D (1.00) | MPOHTR1DHTR1BHTR2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910157-B | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2014-05-07 | — | — | CN | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| EP-2220075-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | MPO 500/4885HTR1D 6/4885HTR1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.